<DOC>
	<DOCNO>NCT01365481</DOCNO>
	<brief_summary>The purpose study ass long-term safety tolerability profile valsartan valsartan-based treatment child hypertension , without chronic kidney disease .</brief_summary>
	<brief_title>Safety Tolerability Valsartan Children 6 17 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Documented diagnosis hypertension able swallow tablet body weight ≥18 kg ≤160 kg baseline MSSBP must ≥ 95th percentile ≤25 % 95th percentile age , gender height . Any clinically significant physical abnormality clinically relevant abnormal laboratory value ( relate renal function ) obtain screen visit . Including follow : 1 . AST/SGOT ALT/SGPT &gt; 3 time upper limit reference range . Patients know active chronic hepatitis exclude . 2 . Total bilirubin &gt; 2 time upper limit reference range 3 . Estimated GFR &lt; 30 mL/min/1.73m² ( calculate use Modified Schwartz Formula ) 4 . WBC count &lt; 3000/mm³ 5 . Platelet count &lt; 100,000/mm³ 6 . Serum potassium &gt; 5.3 mmol/L 7 . Hemoglobin &lt; 8 g/dL Uncontrolled diabetes mellitus Unilateral , bilateral graft renal artery stenosis Current diagnosis heart failure ( New York Heart Association Class IIIV ) Patients take follow concomitant medication follow screening : Reninangiotensin receptor ( RAAS ) blocker study drug , Lithium , potassiumsparing diuretic , potassium supplement , salt substitute contain potassium substance may increase potassium level , Nonsteroidal antiinflammatory drug ( NSAIDS ) , include selective COX2 inhibitor , acetylsalicylic acid &gt; 3g/day , nonselective NSAIDs , Antidepressant drug class Monoamine oxidase ( MAO ) inhibitor ( e.g . phenelzine ) , Chronic use stimulant therapy Attention deficit disorder/attention deficit hyperactivity disorder ( ADD/ADHD ) Patients demonstrate clinically significant ECG abnormality concurrent potentially life threaten arrhythmia symptomatic arrhythmia patient second third degree heart block without pacemaker . Coarctation aorta gradient &gt; =30 mmHg Previous solid organ transplantation except renal transplantation . Patients know positive human immunodeficiency virus ( HIV ) Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion study drug Known suspect contraindication study drug , include severe hepatic impairment , biliary cirrhosis , cholestasis history allergy ARBs and/or angiotensinconverting enzyme ( ACE ) and/or Direct Renin Inhibitors ( DRIs ) History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin . History evidence drug alcohol abuse within last 12 month . Female patient childbearing potential , defined female patient physiologically capable become pregnant , unless willing use highly effective contraception study Pregnant nursing ( lactate ) female patient Participation investigational drug study within 30 day prior screen within 5 elimination halflives study drug prior screening , whichever longer . History hypersensitivity study drug drug similar chemical class . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hypertension , pediatric</keyword>
	<keyword>Hypertension without chronic kidney disease</keyword>
</DOC>